U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 48 results

Status:
US Approved Rx (2023)
First approved in 2011

Class (Stereo):
CHEMICAL (ABSOLUTE)



Crizotinib (trade name Xalkori, Pfizer, Inc.) is an anti cancer drug approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved t...
Status:
US Approved Rx (2023)
First approved in 2009

Class (Stereo):
CHEMICAL (ACHIRAL)



Pazopanib (VOTRIENT) is an orally bioavailable multi-targeted tyrosine kinase receptor inhibitor. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fi...
Status:
US Approved Rx (2009)
First approved in 2009

Class (Stereo):
CHEMICAL (EPIMERIC)



Pralatrexate (PDX or 10-propargyl-10-deazaaminopterin) is a folate analogue that is internalised by the reduced folate carrier 1 (RFC-1) protein, and polyglutamylated by the enzyme folylpolyglutamyl synthetase (FPGS), resulting in accumulation of the...
Status:
US Approved Rx (2018)
First approved in 2007

Class (Stereo):
CHEMICAL (ABSOLUTE)



Temsirolimus is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the FDA in late May 2007, and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a ...
Status:
US Approved Rx (2023)
First approved in 2006

Class (Stereo):
CHEMICAL (ACHIRAL)



Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistan...
Status:
US Approved Rx (2005)
First approved in 2005

Class (Stereo):
CHEMICAL (ACHIRAL)



Sorafenib (BAY 43-9006), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer, hepatocellular carcinoma and for the treatment of patients with locally recurrent or metastatic, pro...
Status:
US Approved Rx (2020)
First approved in 2004

Class (Stereo):
CHEMICAL (ACHIRAL)



Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets th...
Status:
US Approved Rx (2022)
First approved in 2004

Class (Stereo):
CHEMICAL (ABSOLUTE)



Pemetrexed is a new-generation antifolate, approved for the treatment of mesothelioma and non-small cell lung cancer, currently being evaluated for the treatment of a variety of other solid tumors. Pemetrexed, is a folate analog metabolic inhibitor ...
Status:
US Approved Rx (2015)
First approved in 2003

Class (Stereo):
CHEMICAL (ACHIRAL)



Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR t...
Status:
US Approved Rx (2023)
First approved in 1998

Class (Stereo):
CHEMICAL (RACEMIC)



Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right-handed isomers in equal amounts: one enantiomer is effective against morning sickness, and ...